A new study identifies PDE3A mutations as the cause of brachydactyly type E with hypertension. These mutations alter PDE3A activity by uncovering cryptic sites for phosphorylation by PKA and PKC, leading to enzyme hyperactivation that abnormally lowers cAMP levels.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report
BMC Medical Genetics Open Access 06 July 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Maass, P.G. et al. Nat. Genet. 47, 647–653 (2015).
Lugnier, C. Pharmacol. Ther. 109, 366–398 (2006).
Francis, S.H. & Corbin, J.D. Expert Opin. Drug Metab. Toxicol. 1, 283–293 (2005).
Schafer, P.H. et al. Br. J. Pharmacol. 159, 842–855 (2010).
Morales Vidal, S.G. & Ruland, S. Neurol. Clin. 31, 633–657 (2013).
Houslay, M.D. Trends Biochem. Sci. 35, 91–100 (2010).
Vandeput, F. et al. Proc. Natl. Acad. Sci. USA 110, 19778–19783 (2013).
Burgin, A.B. et al. Nat. Biotechnol. 28, 63–70 (2010).
McPhee, I. et al. J. Biol. Chem. 274, 11796–11810 (1999).
Cedervall, P. et al. Proc. Natl. Acad. Sci. USA 112, E1414–E1422 (2015).
Bolger, G.B. et al. Cell. Signal. 27, 756–769 (2015).
Han, S.J. et al. EMBO J. 25, 5716–5725 (2006).
Yan, Y. et al. J. Neurol. Sci. 338, 3–11 (2014).
Kaname, T. et al. Cell. Signal. 26, 2446–2459 (2014).
Abbott-Banner, K.H. & Page, C.P. Basic Clin. Pharmacol. Toxicol. 114, 365–376 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Houslay, M. Hypertension linked to PDE3A activation. Nat Genet 47, 562–563 (2015). https://doi.org/10.1038/ng.3316
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3316
This article is cited by
-
Whole-exome sequencing identifies a de novo PDE3A variant causing autosomal dominant hypertension with brachydactyly type E syndrome: a case report
BMC Medical Genetics (2020)
-
miRNA-27a-3p and miRNA-222-3p as Novel Modulators of Phosphodiesterase 3a (PDE3A) in Cerebral Microvascular Endothelial Cells
Molecular Neurobiology (2019)
-
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals
Nature Genetics (2019)
-
PDE3A gene screening improves diagnostics for patients with Bilginturan syndrome (hypertension and brachydactyly syndrome)
Hypertension Research (2018)